MNPR Stock Analysis: Buy, Sell, or Hold?
MNPR - Monopar Therapeutics Inc. Common Stock
$81.77
13.11 (19.09%)
▲
5d:
+33.02%
30d:
+30.46%
90d:
+45.34%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When MNPR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: MNPR is 20.7% above its trading range ($67.74). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: MNPR is 20.7% above its trading range ($67.74). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: MNPR is currently trading at $81.77, which is considered extended relative to its 30-day fair value range of $57.85 to $67.74.
Technical Outlook: Technically, MNPR is in a uptrend. The price is approaching resistance at $82.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 19.1% recently.
Market Sentiment: MNPR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $112.62 (+37.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MNPR is in a uptrend. The price is approaching resistance at $82.14. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 19.1% recently.
Market Sentiment: MNPR has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $112.62 (+37.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$57.85 -
$67.74
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BEARISH: Price significantly overextended (+20.7% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+19.1%)
- BULLISH: Trading 37.7% below Wall St target ($112.62)
- WARNING: Recommendation downgraded due to 20.7% overvaluation
Trading Range Analysis
30-Day Trading Range
$57.85 -
$67.74
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$58.01
Resistance Level
$82.14
Current Trend
Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-25.85
Wall Street Target
$112.62
(+37.7%)
Share & Embed Analysis
Last updated: June 24, 2026 7:59 AM ET
Data refreshes hourly during market hours. Next update: 8:59 AM
Data refreshes hourly during market hours. Next update: 8:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MNPR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 57 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
